Epigenetics : a new tool for meningioma management?
Menée à partir de l'analyse de 497 échantillons de méningiomes et 309 échantillons de tumeurs crâniennes extra-axiales, cette étude multicentrique évalue, par rapport au système de classification de l'Organisation Mondiale de la Santé, la performance d'un système basé sur le niveau de méthylation de l'ADN pour prédire le risque de récidive et la survie
Although most meningiomas are benign tumours, difficulties can arise as a result of surgical limitations or from aggressive and invasive tumours that need adjuvant treatment with radiotherapy. Existing WHO classifications are highly subjective and lack reliable markers to identify these recurrence-prone tumours. Extensive, high-throughput genomic analyses have comprehensively described the mutational landscape of grade I meningiomas, but did not identify genes involved in malignant progression (except loss of CKDN2A).
The Lancet Oncology , commentaire, 2016